Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medpace Holdings, Inc. - Common Stock (NQ:MEDP)

308.88 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Medpace Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Which stocks are moving before the opening bell on Tuesday?
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Top 2 Health Care Stocks You May Want To Dump This Quarter
Via Benzinga
US Stocks Likely To Open On A Mixed Note Ahead Of Coca-Cola, GM, Lockheed Martin Earnings
U.S. stock futures were fluctuating on Tuesday after ending on a mixed note on Monday. Futures of major benchmark indices were mixed. 
Via Benzinga
Medpace Retail Trader Optimism Abounds As Stock Poised For Best Day Ever On Q2 Beat, Outlook
Via Stocktwits
A Peek at Medpace Hldgs's Future Earnings
Via Benzinga
Why Medpace Shares Are Trading Higher By 45%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Coca-Cola, General Motors And 3 Stocks To Watch Heading Into Tuesday
US stock futures mixed, focus on Coca-Cola, GM, Farmer Bros. Medpace reports strong Q2 results and raises guidance. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Get insights into the top gainers and losers of Monday's after-hours session.
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
Medpace Holdings Stock Soars After Company Tops Q2 Earnings Estimates, Raises 2025 Outlook
Medpace Holdings shares are soaring in Monday's after-hours session after the company reported strong financial results for the second quarter and raised its full-year guidance. 
Via Benzinga
Medpace (NASDAQ:MEDP) Reports Strong Q2, Stock Jumps 46%
Clinical research company Medpace Holdings (NASDAQ:MEDP) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 14.2% year on year to $603.3 million. The company’s... 
Via StockStory
Medpace Holdings, Inc. Reports Second Quarter 2025 Results
From Medpace Holdings, Inc.
Via Business Wire
Earnings Scheduled For July 21, 2025
Via Benzinga
Medpace (MEDP) Q2 Earnings Report Preview: What To Look For
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be reporting results this Monday after market hours. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
Motley Fool Investors Look Back at the First Half of 2025
Via The Motley Fool
Topics Government World Trade
Reflecting On Drug Development Inputs & Services Stocks’ Q1 Earnings: Medpace (NASDAQ:MEDP)
Let’s dig into the relative performance of Medpace (NASDAQ:MEDP) and its peers as we unravel the now-completed Q1 drug development inputs & services earnings season. 
Via StockStory
Medpace Holdings, Inc. to Report Second Quarter 2025 Financial Results on July 21, 2025
From Medpace Holdings, Inc.
Via Business Wire
1 Cash-Producing Stock on Our Watchlist and 2 to Think Twice About
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Topics Intellectual Property
2 Reasons to Watch MEDP and 1 to Stay Cautious
Over the last six months, Medpace’s shares have sunk to $293, producing a disappointing 11.5% loss - a stark contrast to the S&P 500’s 1.7% gain. This may have investors wondering how to approach the... 
Via StockStory
Topics Stocks
2 Small-Cap Stocks to Keep an Eye On and 1 to Think Twice About
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
3 Market-Beating Stocks to Target This Week
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the... 
Via StockStory
2 Profitable Stocks to Target This Week and 1 to Turn Down
A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
Is Medpace Stock Worth the Hype? Here's What Analysts Think.
Via The Motley Fool
2 Unpopular Stocks that Deserve Some Love and 1 to Turn Down
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
Hedge Funds Are Building A Towering Wall Of Bets Against Stocks
After a sharp 23% rebound in the S&P 500 since April, hedge funds are now stacking record levels of bearish bets against stocks as investors question the staying power of the tariff-relief rally. 
Via Benzinga
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides... 
Via StockStory
Topics Government Stocks World Trade
MEDP Q1 Earnings Call: Outperformance Driven by Revenue Upside, Cautious Outlook Amid Funding Uncertainty
Clinical research company Medpace Holdings (NASDAQ:MEDP) announced better-than-expected revenue in Q1 CY2025, with sales up 9.3% year on year to $558.6 million. The company’s full-year revenue guidance... 
Via StockStory
Topics Economy
If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year? 
Via Investor's Business Daily
Topics Animal Testing Economy Government
Repligen (RGEN) Q1 Earnings: What To Expect
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what to look for. 
Via StockStory
Topics World Trade
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.